ACE2 and infection: We found that DG treatment at non-toxic doses could dose-dependently reduce infection with pseudotyped SARS-CoV-2, as well as various variants of concern (Wuhan-Hu-1, P.1, B.1.617., B.1.351, and BA.2), but had no effect on VSV pseudovirus in hACE2-expressing 293T cells (Figure 4A–F and Figure S1), indicating that DG could specifically block viral S protein-mediated entry by ACE2.